Cargando…

High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial

IMPORTANCE: Acute bacterial sinusitis is common, but currently recommended antibiotic treatment provides minimal benefit. OBJECTIVE: To confirm the previous finding that high-dose amoxicillin plus clavulanate (with double the amount of amoxicillin) may be superior to standard-dose amoxicillin plus c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregory, Jennifer, Huynh, Bichtram, Tayler, Brittany, Korgaonkar-Cherala, Chaitali, Garrison, Gina, Ata, Ashar, Sorum, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988367/
https://www.ncbi.nlm.nih.gov/pubmed/33755168
http://dx.doi.org/10.1001/jamanetworkopen.2021.2713
_version_ 1783668776778072064
author Gregory, Jennifer
Huynh, Bichtram
Tayler, Brittany
Korgaonkar-Cherala, Chaitali
Garrison, Gina
Ata, Ashar
Sorum, Paul
author_facet Gregory, Jennifer
Huynh, Bichtram
Tayler, Brittany
Korgaonkar-Cherala, Chaitali
Garrison, Gina
Ata, Ashar
Sorum, Paul
author_sort Gregory, Jennifer
collection PubMed
description IMPORTANCE: Acute bacterial sinusitis is common, but currently recommended antibiotic treatment provides minimal benefit. OBJECTIVE: To confirm the previous finding that high-dose amoxicillin plus clavulanate (with double the amount of amoxicillin) may be superior to standard-dose amoxicillin plus clavulanate in adults. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, comparative-effectiveness randomized clinical trial was conducted from February 26, 2018, through May 10, 2020, at the academic primary care internal medicine and pediatrics practice of Albany Medical Center, located in Cohoes, New York. Participants included adults aged 18 years or older who were prescribed amoxicillin plus clavulanate for acute bacterial sinusitis diagnosed in accordance with the Infectious Diseases Society of America guidelines. INTERVENTIONS: Amoxicillin 875 mg with clavulanate 125 mg plus either placebo (standard dose) or amoxicillin 875 mg (high dose) twice a day for 7 days. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a global rating of “a lot better” or “no symptoms” at the end of 3 days of treatment using a Global Rating of Improvement scale, with outcomes ranging from 1 (a lot worse) to 6 (no symptoms). The primary adverse effect outcome was severe diarrhea at 3 or 10 days after the start of treatment. RESULTS: At an unplanned interim analysis prompted by COVID-19 restrictions, 157 of a projected 240 participants had been enrolled (mean age, 48.5 [range, 18.7-84.0] years; 117 women [74.5%]), with 79 randomized to the standard dose and 78 to the high dose; 9 and 12, respectively, withdrew or were lost to follow-up before the assessment of the primary outcome. At day 3, 31 of 70 participants (44.3%) in the standard-dose group reported a global rating of “a lot better” or “no symptoms,” as did 24 of 66 (36.4%) in the high-dose group, for a difference of −7.9% (95% CI, −24.4% to 8.5%; P = .35). The study was, therefore, stopped for futility. Diarrhea was common in both groups by day 3, with any diarrhea reported in 29 of 71 participants (40.8%) receiving the standard dose and 28 of 65 (43.1%) receiving the high dose and severe diarrhea reported in 5 of 71 (7.0%) and 5 of 65 (7.7%), respectively. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that adults treated for clinically diagnosed acute sinusitis did not appear to benefit from taking high-dose compared with standard-dose amoxicillin plus clavulanate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03431337
format Online
Article
Text
id pubmed-7988367
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-79883672021-04-12 High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial Gregory, Jennifer Huynh, Bichtram Tayler, Brittany Korgaonkar-Cherala, Chaitali Garrison, Gina Ata, Ashar Sorum, Paul JAMA Netw Open Original Investigation IMPORTANCE: Acute bacterial sinusitis is common, but currently recommended antibiotic treatment provides minimal benefit. OBJECTIVE: To confirm the previous finding that high-dose amoxicillin plus clavulanate (with double the amount of amoxicillin) may be superior to standard-dose amoxicillin plus clavulanate in adults. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, comparative-effectiveness randomized clinical trial was conducted from February 26, 2018, through May 10, 2020, at the academic primary care internal medicine and pediatrics practice of Albany Medical Center, located in Cohoes, New York. Participants included adults aged 18 years or older who were prescribed amoxicillin plus clavulanate for acute bacterial sinusitis diagnosed in accordance with the Infectious Diseases Society of America guidelines. INTERVENTIONS: Amoxicillin 875 mg with clavulanate 125 mg plus either placebo (standard dose) or amoxicillin 875 mg (high dose) twice a day for 7 days. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a global rating of “a lot better” or “no symptoms” at the end of 3 days of treatment using a Global Rating of Improvement scale, with outcomes ranging from 1 (a lot worse) to 6 (no symptoms). The primary adverse effect outcome was severe diarrhea at 3 or 10 days after the start of treatment. RESULTS: At an unplanned interim analysis prompted by COVID-19 restrictions, 157 of a projected 240 participants had been enrolled (mean age, 48.5 [range, 18.7-84.0] years; 117 women [74.5%]), with 79 randomized to the standard dose and 78 to the high dose; 9 and 12, respectively, withdrew or were lost to follow-up before the assessment of the primary outcome. At day 3, 31 of 70 participants (44.3%) in the standard-dose group reported a global rating of “a lot better” or “no symptoms,” as did 24 of 66 (36.4%) in the high-dose group, for a difference of −7.9% (95% CI, −24.4% to 8.5%; P = .35). The study was, therefore, stopped for futility. Diarrhea was common in both groups by day 3, with any diarrhea reported in 29 of 71 participants (40.8%) receiving the standard dose and 28 of 65 (43.1%) receiving the high dose and severe diarrhea reported in 5 of 71 (7.0%) and 5 of 65 (7.7%), respectively. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial suggest that adults treated for clinically diagnosed acute sinusitis did not appear to benefit from taking high-dose compared with standard-dose amoxicillin plus clavulanate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03431337 American Medical Association 2021-03-23 /pmc/articles/PMC7988367/ /pubmed/33755168 http://dx.doi.org/10.1001/jamanetworkopen.2021.2713 Text en Copyright 2021 Gregory J et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Gregory, Jennifer
Huynh, Bichtram
Tayler, Brittany
Korgaonkar-Cherala, Chaitali
Garrison, Gina
Ata, Ashar
Sorum, Paul
High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial
title High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial
title_full High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial
title_fullStr High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial
title_full_unstemmed High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial
title_short High-Dose vs Standard-Dose Amoxicillin Plus Clavulanate for Adults With Acute Sinusitis: A Randomized Clinical Trial
title_sort high-dose vs standard-dose amoxicillin plus clavulanate for adults with acute sinusitis: a randomized clinical trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988367/
https://www.ncbi.nlm.nih.gov/pubmed/33755168
http://dx.doi.org/10.1001/jamanetworkopen.2021.2713
work_keys_str_mv AT gregoryjennifer highdosevsstandarddoseamoxicillinplusclavulanateforadultswithacutesinusitisarandomizedclinicaltrial
AT huynhbichtram highdosevsstandarddoseamoxicillinplusclavulanateforadultswithacutesinusitisarandomizedclinicaltrial
AT taylerbrittany highdosevsstandarddoseamoxicillinplusclavulanateforadultswithacutesinusitisarandomizedclinicaltrial
AT korgaonkarcheralachaitali highdosevsstandarddoseamoxicillinplusclavulanateforadultswithacutesinusitisarandomizedclinicaltrial
AT garrisongina highdosevsstandarddoseamoxicillinplusclavulanateforadultswithacutesinusitisarandomizedclinicaltrial
AT ataashar highdosevsstandarddoseamoxicillinplusclavulanateforadultswithacutesinusitisarandomizedclinicaltrial
AT sorumpaul highdosevsstandarddoseamoxicillinplusclavulanateforadultswithacutesinusitisarandomizedclinicaltrial